ORx Pharmaceuticals

ORx Pharmaceuticals is a Canadian specialty pharmaceutical and advanced drug-delivery company focused on reformulating and developing improved oral dosage forms of existing and promising drug compounds. The company specializes in technologies intended to enhance oral absorption, bioavailability, controlled release, and tissue targeting for drugs that have poor or suboptimal performance in conventional formulations. Its disclosed pipeline includes GlycoBien for diabetes, Leptivia for obesity, and Orazephin, an oral ceftriaxone product for antibacterial use. ORx also markets its HydroMatrix controlled-release platform and OraRem oral reverse-micellar delivery platform for licensing, co-development, and life-cycle management opportunities. The company appears to operate as a private, platform-oriented pharma business with activities spanning product development, clinical testing, and strategic partnerships.